Nineteen-year-old law student Josephine Nasr died of a cardiac arrhythmia while studying abroad in London. Authorities discovered an empty vial of Tirzepatide in her room at the University of East London. Nasr had been prescribed the drug in California for weight management. Her family reported that she had been suffering from nausea and vomiting before her death.
Coroner Graeme Irvine concluded the cause of death was myocardial bridging and an electrolyte imbalance resulting from hypoglycemia. These conditions were directly attributed to the use of the prescribed medication. Tirzepatide is a dual GIP and GLP-1 receptor agonist commonly marketed as Mounjaro or Zepbound. Medical literature acknowledges that nausea and vomiting are known side effects of this class of drugs.
Nasr was described by her family as a joyful person committed to helping others. Her passing serves as a stark reminder of the risks associated with potent weight loss pharmaceuticals. Medical experts continue to evaluate the safety protocols surrounding these prescriptions as their usage increases globally.